Generic and proprietary pharmaceuticals manufacturer Barr Pharmaceuticals (BRL) said Thursday that it can now acquire Shire's Adderall, which it had agreed to buy on Aug. 14 through its subsidiary Duramed Pharmaceuticals, as the Hart-Scott-Rodino waiting period for the acquisition has expired without further action from the Federal Trade Commission.
Under terms of the agreement, the Woodcliff lake, N.J.-based company will pay $63 million to purchase Shire's Adderall immediate-release mixed amphetamine salts tablets.
Barr said it will launch the Adderall product in the fourth quarter.
Adderall is indicated as an integral part of a total treatment program, which typically includes other remedial measures for a stabilizing effect in children with behavioral disorders.
Shares of Barr were trading up 7 cents to $52.14 Thursday.
This story was created through a joint venture between TheStreet.com and IRIS.